BY ALEXANDRA BELAYEW, MONS, BELGIUM DUX4, the gene that plays a key role in facioscapulohumeral muscular dystrophy (FSHD), is gaining unexpected notoriety in cancer research. According to a recent study1… Read More »
FSHD Gene May Help Tumors Evade the Immune System
Fulcrum Announced Results of Phase 1 Clinical Trial of Losmapimod
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy. CAMBRIDGE, Mass., Oct. 04, 2019… Read More »
FSHD Society Announces 2020 Conferences
The nation’s capital will host the world’s premier conferences on facioscapulohumeral muscular dystrophy for all stakeholders. REGISTER HERE. The FSHD Society’s 27th annual International Research Congress (IRC) will be held… Read More »
Dyne Therapeutics to support ReSolve study of FSHD
From BusinessWire Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced its support for the ReSolve study, an ongoing natural history study designed… Read More »
Disappointing news from Acceleron
From Acceleron’s press release Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment… Read More »